You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: June 1, 2020

DrugPatentWatch Database Preview

Patent: 10,017,492

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,017,492

Title:	Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
Abstract:	Provided are an isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof. The isoindoline derivative and the pharmaceutical composition thereof can regulate the production or activity of immunological cytokines, thus effectively treating cancer and inflammatory disease. ##STR00001##
Inventor(s):	Ge; Chuansheng (Shanghai, CN), Lee; Wen-Cherng (Shanghai, CN), Liao; Baisong (Shanghai, CN), Zhang; Lei (Shanghai, CN)
Assignee:	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)
Application Number:	15/523,651
Patent Claims:	see list of patent claims

Details for Patent 10,017,492

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26	Start Trial	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	2034-10-30	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	002	1997-11-26	Start Trial	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	2034-10-30	RX		search
Genentech	HERCEPTIN	trastuzumab	VIAL; INTRAVENOUS	103792	001	1998-09-25	Start Trial	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	2034-10-30	RX	Orphan	search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	Start Trial	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	2034-10-30	RX		search
Bristol Myers Squibb	OPDIVO	nivolumab	INJECTABLE;INJECTION	125527	001	2015-03-04	Start Trial	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	2034-10-30	RX		search
Bristol Myers Squibb	OPDIVO	nivolumab	INJECTABLE;INJECTION	125527	002	2015-03-04	Start Trial	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	2034-10-30	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 10,017,492

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2015341301	Start Trial
Canada	2966038	Start Trial
China	105566290	Start Trial
European Patent Office	3214081	Start Trial
Japan	2017533955	Start Trial
Japan	6546997	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic

AstraZeneca

Express Scripts

Boehringer Ingelheim

Harvard Business School

Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.